You Are Here: Home » News of the world » Regenerative Medicine » Asterias Biotherapeutics, Inc. (AST) EPS Estimated At $-0.12 on May, 10

Asterias Biotherapeutics, Inc. (AST) EPS Estimated At $-0.12 on May, 10

Asterias Biotherapeutics, Inc. (AST) EPS Estimated At $-0.12 on May, 10

Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapies in the fields of cell therapy and regenerative medicine.The firm is worth $70.46 million. The firm develops therapeutic products in the areas of neurology and oncology.

Leave a Comment

Current month ye@r day *

Scroll to top